Ionis Pharmaceuticals (IONS) Shares Outstanding (Weighted Average) (2009 - 2026)

Ionis Pharmaceuticals has reported Shares Outstanding (Weighted Average) for 18 years, with the latest figure at $164.9 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 3.87% year-over-year to $164.9 million; the trailing twelve-month figure through Mar 2026 stood at $164.9 million (up 3.87% YoY), and the FY2025 full-year result was $159.1 million, up 6.44% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $164.9 million, up from $160.0 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $164.9 million in Q1 2026, with the low at $141.6 million in Q1 2022.
• Average Shares Outstanding (Weighted Average) over 5 years is $148.8 million, with a median of $145.5 million recorded in 2024.
• Year-over-year, Shares Outstanding (Weighted Average) increased 0.59% in 2022 and climbed 9.07% in 2025.
• Tracing IONS's Shares Outstanding (Weighted Average) over 5 years: stood at $141.8 million in 2022, then increased by 0.95% to $143.2 million in 2023, then climbed by 4.42% to $149.5 million in 2024, then climbed by 7.02% to $160.0 million in 2025, then increased by 3.04% to $164.9 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $164.9 million (Q1 2026), $160.0 million (Q4 2025), and $159.8 million (Q3 2025), per Business Quant data.

Peer Comparison